Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619316 | 0.94 | ALDH1A1 (0.39) | KDM4EPOLBLMNAMAPK1ALDH1A1 | |
| SCHEMBL3614687 | 0.84 | DDR1 (0.37) | KDM4EPOLBALDH1A1DDR1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL3615430 | 0.82 | KDM4E (0.38) | KDM4EPOLBLMNAMAPK1ALDH1A1 | |
| SCHEMBL3614586 | 0.81 | DDR1 (0.36) | KDM4EPOLBALDH1A1TP53DDR1 | |
| SCHEMBL3619350 | 0.80 | ALDH1A1 (0.39) | KDM4EPOLBLMNAMAPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3619313 | 0.76 | ALDH1A1 (0.42) | KDM4EPOLBLMNAMAPK1ALDH1A1 | |
| SCHEMBL3622100 | 0.75 | HTR6 (0.44) | KDM4ETP53 | |
| SCHEMBL13120048 | 0.73 | ALDH1A1 (0.45) | KDM4EPOLBLMNAMAPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3622099 | 0.70 | HTR6 (0.54) | TP53 | |
| SCHEMBL3619784 | 0.67 | HTR6 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | KDM4E 3665/4885POLB 3884/4885LMNA 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.